When your pharmacy can give you a headache: a prescription for dispensing practices

7 February 2019
By Charlotte Goodson

 Charlotte GoodsonAs with any change, the drive to deliver primary care at scale carries with it the risk of unintended consequences. 

 
For a dispensing practice looking to merge or to move to shiny new premises, the loss of a valuable income stream from dispensing can be one.
 
PCC primary care adviser Charlotte Goodson cautions that the regulations in this area are particularly opaque and complex and dispensing practices need to take stock when planning changes.
 
“Practice partners and managers need to be aware of the evolving regulations and the way they are being interpreted. This is complicated for them by the fact that while their clinical commissioning group might support – and even promote – a merger or moving into new premises, issues around dispensing are decided by NHS England.”
 
“Practices really need to understand what the regulations say and to talk to their local NHS England team well in advance of any merger or move. Decisions around local medical services are decided at CCG level but dispensing decisions lie with NHS England because they are pharmaceutical services.”
 
Goodson, who delivers PCC’s courses on dispensing requirements, says: “If practices are looking to merge or to move into new premises or to start dispensing from additional premises, they have to get fresh approval. Sometimes the discussions they need to have don’t start early enough. They really need to talk to their NHS England local team at an early stage. Decisions on applications for changes to the dispensing service will take up to four months and are subject to appeal. Even if the practice’s application to move is granted, their ability to dispense would be threatened if a business has submitted an application to open a pharmacy within 1.6km of the new premises. This could mean they lose their right to dispense from the new site or it could delay dispensing  for up to 12 months.”
 
“I’ve heard of a case where a practice called NHS England on the Friday afternoon to confirm arrangements for opening up and dispensing in new premises on the following Monday.”
 
The complex rules – including the widelydisliked “one mile rule” – apply to practices which dispense medicines rather than those with fully-fledged pharmacies.
However, if a co-located pharmacy is moving with the practice that also is an added complication the practice needs to consider.
 
Even NHS England cannot guarantee that dispensing status will be preserved if the practice location changes or it is involved with a merger. In some cases, CCGs supporting a practice move as part of their estates strategy are finding out late in the day that there is a significant barrier in the way.
 
The one mile rule generally prevents practices dispensing medication if there is a pharmacy within that radius. Goodson has heard of cases where the new site for an existing practice is safely at least a mile from the nearest pharmacy only for an application to come in for a new pharmacy. The practice can only continue dispensing if the pharmacy application is refused or if the pharmacy doesn’t open.
 
That can be a particular issue where a new residential development is underway. Hundreds of new homes might attract both an existing dispensing practice and a pharmacy. 
 
Goodson says: “These issues are very political in rural areas in particular and the system does have its flaws but it’s unlikely to change in the foreseeable future.”
 
Until then, her sessions for practices and CCGs explaining the regulations and their practical implications are likely to remain popular. Goodson can also provide specific tailored advice to any dispensing practice that is considering merging or relocating.
 
PCC provides support for practices and commissioners to manage contracting issues around dispensing. Contact enquiries@pcc-cic.org.uk
Resources Commissioning and contracting Primary medical

Latest News

New code of conduct for AI systems

20 February 2019

The Department of Health and Social Care has issued a code of conduct for artificial intelligence (AI) and other data-driven technologies will ensure that only the best and safest systems are used by the NHS.

The code encourages technology companies to meet a gold-standard set of principles to protect patient data to the highest standards. It has been drawn up with the help of industry, academics and patient groups.

The aim is to make it easier for suppliers to develop technologies that tackle some of the biggest issues in healthcare, such as dementia, obesity and cancer. It will also help health and care providers choose safe, effective and secure technology to improve the services they provide.

Read More

More on GMS contract changes 2019/20

20 February 2019

NHS England has written to directors of primary care and senior CCG managers with further details of changes to the GMS contract for 2019/20. It includes notification of the one-off payment for indemnity inflation, changes to the value of QOF, global sum and out-of-hours payments, and the £1.761 per weighted patient for signing up to the forthcoming network contract directed enhanced service (DES).

Read More

Tobacco control assessment tools

19 February 2019

Self-assessment tools from Public Health England help local public health bodies to scrutinise their tobacco control work.

Read More

EU advice notice on falsified medicines directive

19 February 2019

The Safety Features Delegated Regulation, part of the EU Falsified Medicines Directive (FMD), will apply in the UK from 9 February 2019. Healthcare institutions are required to verify and decommission medicines supplied or administered directly to patients. All GP practices “personally administer” some medications and the decommissioning of these elements are covered by the GPIT operating model arrangements and centrally funded. According to the Medicines and Healthcare products Regulatory Agency (MHRA) FMD requirements would need to removed from law in the event of a no deal EU exit as we would no longer have access to the EU system. FMD preparations need to continue “with appropriate caution” given the possibility of a no deal scenario, the MHRA says.

Read More

NICE draft guidance recommends pertuzumab for early treatment of breast cancer

19 February 2019

NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.

Read More